BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30544367)

  • 1. The clinical outcomes of S-1 plus cisplatin for patients with advanced gastric cancer: A meta-analysis and systematic review.
    Yang L; Wang X; Wang B; Chao P; Li D; Chai C
    Medicine (Baltimore); 2018 Dec; 97(49):e12789. PubMed ID: 30544367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
    Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
    Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
    Luo D; Wang L; Chen X; Xiong Y; Yi F; Ding J; Ding H; Wei Y; Zhang W
    Chemotherapy; 2020; 65(1-2):11-20. PubMed ID: 32535588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.
    Wu FL; Lu DC; Ying YP; Huang JJ; Zhou AM; Jiang DK; Chen MW; Yang X; Zhou J; Huang HQ; Zeng HY
    Medicine (Baltimore); 2015 Apr; 94(16):e652. PubMed ID: 25906091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
    Bian NN; Wang YH; Min GT
    Int J Surg; 2019 Feb; 62():34-43. PubMed ID: 30641155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a meta-analysis.
    Wu JR; Tang WZ; Chen X; Xie YT; Chen SY; Peng QL; Xie L; Deng Y; Li TJ; He Y; Wang J; Li S; Qin X
    Tumour Biol; 2014 Apr; 35(4):3283-93. PubMed ID: 24390661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: a meta-analysis.
    Liu GF; Tang D; Li P; Wang S; Xu YX; Long AH; Zhou NL; Zhang LL; Chen J; Xiang XX
    World J Gastroenterol; 2014 Jan; 20(1):310-8. PubMed ID: 24415887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis.
    Huang J; Cao Y; Wu L; Liao C; He Y; Gao F
    Med Oncol; 2011 Dec; 28(4):1004-11. PubMed ID: 20552300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-1 (Teysuno®): a review of its use in advanced gastric cancer in non-Asian populations.
    Sanford M
    Drugs; 2013 Jun; 73(8):845-55. PubMed ID: 23719766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
    Zhang Q; Qian Y; Yin Y
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1791-1804. PubMed ID: 34275019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.
    Li DH; Pan ZK; Ye F; An HX; Wu JX
    Tumour Biol; 2014 Aug; 35(8):8201-8. PubMed ID: 24850178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer.
    Kang BW; Kim JG; Chae YS; Lee YJ; Lee SJ; Moon JH; Sohn SK; Jung MK; Jeon SW; Jang YJ; Seo J; Lee YH; Kwon O; Chung HY; Yu W
    Invest New Drugs; 2012 Aug; 30(4):1671-5. PubMed ID: 21845514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis.
    Chen XD; He FQ; Chen M; Tang LC; Tang XL
    Medicine (Baltimore); 2016 Jun; 95(24):e3916. PubMed ID: 27310997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
    Feng Z; Yan P; Hou X; Feng J; He X; Yang K
    Ann Palliat Med; 2020 May; 9(3):883-894. PubMed ID: 32389017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
    Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
    Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
    Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
    Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.
    Ter Veer E; Mohammad NH; Lodder P; Ngai LL; Samaan M; van Oijen MG; van Laarhoven HW
    Gastric Cancer; 2016 Jul; 19(3):696-712. PubMed ID: 26754295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.